Intra Cellular Therapies | ITCI - أصول متداولة



أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
BioCryst Pharmaceuticals USD 484.68M 111.06M 2026-06
Biogen USD 7.31B 1.88B 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Cytokinetics USD 1.21B 369.02M 2026-06
Gilead Sciences USD 12.53B 6.11B 2026-06
Halozyme Therapeutics USD 933.02M 70.01M 2026-06
J&J USD 59.77B 601M 2026-06
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novartis USD 26.61B 3.85B 2026-03
Prothena USD 292.01M 47.19M 2026-06
RedHill Biopharma USD 6.53M 6.03M 2025-12
Supernus Pharmaceuticals USD 723.5M 8.08M 2026-06
United Therapeutics USD 3.48B 611.7M 2026-06
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12